Recent developments of HDAC inhibitors: Emerging indications and novel molecules

Andrey D. Bondarev(Uppsala University), Helgi B. Schiöth(Uppsala University)

British Journal of Clinical Pharmacology

May 10, 2021

10.1111/bcp.14889

Cited by 407

Related Papers

Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate

|Biochemical Pharmacology|2019|30

Hydroxymethylglutaryl‐CoA reductase activity is essential for mitochondrial β‐oxidation of fatty acids to prevent lethal accumulation of long‐chain acylcarnitines in the mouse liver

|British Journal of Pharmacology|2024|13